# NWRD06 DNA Plasmid for HCC After Curative Resection.

> **NCT07324304** · PHASE2 · RECRUITING · sponsor: **Newish Technology (Beijing) Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **BIOLOGICAL:** NWRD06 administered by electroporation

## Key facts

- **NCT ID:** NCT07324304
- **Lead sponsor:** Newish Technology (Beijing) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07324304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07324304, "NWRD06 DNA Plasmid for HCC After Curative Resection.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07324304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*